Navigation Links
Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Date:6/18/2013

NESS ZIONA, Israel, June 18, 2013 /PRNewswire/ --

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US and Europe for the oral treatment of moderate-to-severe acute pain.

US Patent number 8,410,176 B2 is titled Intermediate Compounds and Processes for the Preparation of Tapentadol and Related Compounds. Mapi's innovative process enables the company to obtain Tapentadol in an optically active pure form.  The process is cost effective, uses easily available reagents and fits scalable industrial processes.

Tapentadol is indicated for the relief of moderate-to-severe acute pain. This segment of pain relievers has continuously grown during the last decade as a result of improved delivery technologies, increased physician recognition of the need for effective pain treatment, and the rising requirement for pain medication by the growing ageing population.  

"The patent acceptance announced today is Mapi's second in just one month. The first was for a long acting depot formulation of Glatiramer Acetate for the treatment of MS. Both patents strengthen Mapi's patent position, support the business plan and advance the company one step closer to bringing patients improved medications at affordable prices," said Mapi Pharma President & CEO Mr. Ehud Marom. "The pain relief market requires a specific expertise in dealing with potent pharmaceuticals. Mapi is uniquely positioned to answer the growing needs of this market."

The moderate-to-severe acute pain relief market is a growing therapeutic area. It is currently estimated at about US $10 billion and is expected to continue expanding for the foreseeable future.  

About Mapi-Pharma

Mapi Pharma (Mapi) is an international pharmaceutical company specializing in complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high development barrier generics and novel finished dosage forms based on selected drug delivery systems. Mapi is focused on developing innovative delivery systems for pharmaceuticals such as long acting depot injections. Mapi has an extensive pipeline of medications that will follow the FDA regulatory pathway 505(b)(2). The company is built on the strong chemical and pharmaceutical R&D capabilities of its founders, a deep understanding of the global market and of regulatory needs and its ability to foster local cooperation and enduring relationships in all of the countries in which it is present. Mapi is dedicated to providing generic and innovative intermediates & APIs as well as developing finished dosage forms - either to Mapi's internal API program, as a vertically integrated company, or generically, to other leading brands. Mapi is headquartered in Israel.  It has R&D facilities in Israel, China and Germany and is currently building an API manufacturing site in Neot Hovav, Israel's designated chemical park. The company has a strong IP position, filing more than 20 patent applications for APIs and formulations in less than three years since it began operations. For more information: http://www.mapi-pharma.com

Press Contact:
Marjie Hadad
Media Liaison
Mapi Pharma
marjie@mapi-pharma.com
+972-54-536-5220


'/>"/>
SOURCE Mapi Pharma Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2019)... ... May 21, 2019 , ... DuPont Nutrition ... opened the inaugural Africa Brewing Conference dedicated to sharing brewing knowledge, strengthening relationships ... event, which is supported through a partnership with “Ethiopia Invest”, will run through ...
(Date:5/14/2019)... TOWNSHIP, N.J. (PRWEB) , ... May 13, 2019 ... ... of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, Medical Device ... new Heliumleak.com company website. The redesigned website aims to improve LDA’s ability to ...
(Date:5/7/2019)... ... May 06, 2019 , ... "The new Liquid Nitrogen Best ... being asked to store cellular products being used in adoptive therapy research ... world leaders, who have shared their expertise in building and managing facilities to ...
(Date:5/2/2019)... ... April 30, 2019 , ... ... Standardization ISO 9001:2015 standard, REPROCELL USA Inc. has demonstrated its ability to ... REPROCELL USA Inc. aims to enhance customer satisfaction through the effective implementation ...
Breaking Biology Technology:
(Date:7/17/2019)... ... July 16, 2019 , ... Imagine using a simple, portable test to ... before it causes osteoporosis. For South Dakota School of Mines & Technology researcher Congzhou ... in terms of our ability to monitor and prevent disease,” says Wang. , ...
(Date:7/9/2019)... Del. (PRWEB) , ... July 08, 2019 , ... ... Court ruled in favor of Danisco’s ownership of the innovation behind two Danisco ... that an entitlement action could be based on prior art was without merit ...
(Date:6/20/2019)... , ... June 19, 2019 , ... ... by the Infectious Diseases Society of America Foundation, and the possibly millions of ... to study infectious agents in AD, are a “welcome affirmation” of the need ...
Breaking Biology News(10 mins):